The David Scheinberg Lab

The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes antibodies, targeted nano-devices, engineered cells, and active specific agents such vaccines. An important goal is to take these new therapies into human clinical trials for testing. Examples include a molecular nanogenerator that releases alpha particles inside cancer cells, now being tested in Phase II human trials and a vaccine to WT1 about to enter Phase III trials. Read full article in Science. A WT1 vaccine is also in late stage national trials (Blood, 2010).

We have developed targeted alpha particle therapies, targeted beta emitters, oncogenic protein peptide vaccines, humanized antibodies, each of which reached human clinical trials; More recently we have discovered TCR mimic antibodies to intracellular proteins (Science Trans. Med., 2013), (Nature Biotech., 2015), as well as prototype targeted nano-machines (Nature Nano, 2013)

David Scheinberg

David A. Scheinberg, MD, PhD

Chair, Molecular Pharmacology Program, SKI; Director, Center for Experimental Therapeutics, MSK


Research Focus

Molecular Pharmacology Program Chair David Scheinberg focuses on the discovery and development of novel, specific immunotherapeutic agents and targeted nanodevices for cancer therapy.


MD, PhD, Johns Hopkins University School of Medicine

Lab Members